Page last updated: 2024-08-24

atorvastatin and etc-1002

atorvastatin has been researched along with etc-1002 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's4 (100.00)2.80

Authors

AuthorsStudies
Banach, M; Penson, PE1
Hanselman, JC; MacDougall, DE; Nicholls, SJ; Rubino, J; Sterling, LR1
Amore, BM; Barrett, PHR; Catapano, AL; Chapel, S; Crass, RL; Emery, MG; Jadhav, SB; Kerschnitzki, M; Sasiela, WJ; Watts, GF1
Geiling, JA; Haxhikadrija, P; Lauer, B; Makhmudova, U; Maloku, A; Möbius-Winkler, S; Otto, S; Römer, R; Samadifar, B; Schulze, PC; Weingärtner, O1

Trials

1 trial(s) available for atorvastatin and etc-1002

ArticleYear
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis, 2021, Volume: 320

    Topics: Anticholesteremic Agents; Atorvastatin; Dicarboxylic Acids; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Treatment Outcome

2021

Other Studies

3 other study(ies) available for atorvastatin and etc-1002

ArticleYear
Lipid-lowering therapies: Better together.
    Atherosclerosis, 2021, Volume: 320

    Topics: Atorvastatin; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia

2021
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model.
    European heart journal. Cardiovascular pharmacotherapy, 2022, Sep-03, Volume: 8, Issue:6

    Topics: Atorvastatin; Cholesterol, LDL; Dicarboxylic Acids; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin

2022
Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").
    Clinical research in cardiology : official journal of the German Cardiac Society, 2023, Volume: 112, Issue:9

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Prospective Studies; ST Elevation Myocardial Infarction; Treatment Outcome

2023